APR-246 in Combination With Azacitidine for TP53 Mutated AML (Acute Myeloid Leukemia) or MDS (Myelodysplastic Syndromes) Following Allogeneic Stem Cell Transplant
Clinical trial NCT03931291 · COMPLETED
Trial details
- NCT number
- NCT03931291
- Sponsor
- Aprea Therapeutics
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2019-09-16
- Primary completion
- 2021-08-27
- Enrollment
- 33
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.